In prostate cancer, previous study shows that miR-34a is a key negative regulator of CD44+ prostate cancer cells and establishes a strong rationale for developing miR-34a as a novel therapeutic agent against prostate CSCs [14]. This evidence concerns the gene CD44 and Familial prostate cancer.